APR 23, 2020 11:39 AM PDT

Dual Inhibition from One Chemotherapy

WRITTEN BY: Jasper Cantrell

Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary chemotherapeutic targets are usually receptor tyrosine kinases. One such kinase is called FLT3. FLT3 is a receptor tyrosine kinase that initiates several downstream pathways involved in cellular proliferation, including Akt, mTOR, and several others. Specific mutations called internal tandem repeats, or FLT3-ITD, cause uncontrolled activation of FLT3 and its downstream pathways. This uncontrolled activation quickly leads to cancer transformation. While several inhibitors exist for FLT3, they all suffer from minor complications, and cancers treated with them were prone to generate resistance against them.

A group from the United Kingdom began an investigation into a new dual inhibitor, CCT241736, that seemed to overcome the issues seen in other FLT3 inhibitors. This new compound had been shown previously to bind to both FLT3, and another kinase called aurora kinase. The aurora kinase is involved in mitosis, and inhibition can result in cell cycle arrest, which can induce cell death. They began their testing by measuring CCT241736 against other aurora kinase inhibitors on AML cell lines in vitro. Standard inhibitors exhibited mixed results, where CCT241736 produced proper cell cycle arrest that induced cell death. This result proved its efficacy in selective inhibition of aurora kinase over other inhibitors.

Next, they decided to examine CCT241736s FLT3 inhibitory abilities. It was shown in previous work that the resistance developed by cancer cells was due to secondary mutations on top of the original ITD. Testing CCT241736 on a screen of FLT3 inhibitor-resistant AML cell lines revealed that CCT241736 was tens of times more potent in its suppression of growth when compared to other FLT3 inhibitors. Mouse experiments confirmed this, and no resistance developed against CCT241736 even after 107 days of treatment. This data suggests that CCT241736 uniquely interacts with FLT3 that, that prevents resistance by new mutations seen in other inhibitors.

The dual inhibitory capabilities of CCT241736 FLT3 and aurora kinase make it a great candidate for possible chemotherapy. Its oral bioavailability and low blood clearance are big pluses in actual treatment as well. The actual mechanism by which CCT241736 inhibits both FLT3 and aurora kinase still needs to be investigated. However, the results of this paper make CFT241736 an attractive target for future chemotherapy research.

Sources: Blood Advances, OncLiveTV
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUN 11, 2021
Cancer
Man beats brain cancer with ketogenic diet
JUN 11, 2021
Man beats brain cancer with ketogenic diet
Glioblastoma brain cancer continues to be one of the most fatal cancers, responsible for approximately 15,000 death ever ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
JUN 16, 2021
Cell & Molecular Biology
A Potential Way to Prevent Metastatic Cancer
JUN 16, 2021
A Potential Way to Prevent Metastatic Cancer
Metastatic cancer is the deadliest, and it can happen years after cancer has been treated to the point of remission. Met ...
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
OCT 21, 2021
Cancer
Exercise: A Secret Weapon to Combat Prostate Cancer?
OCT 21, 2021
Exercise: A Secret Weapon to Combat Prostate Cancer?
Exercise oncology is an evolving science that considers the addition of physical activity regimens to the treatment ...
OCT 12, 2021
Immunology
Cancer Drug Helps Alzheimer's Mice Remember
OCT 12, 2021
Cancer Drug Helps Alzheimer's Mice Remember
What if a drug—specifically developed to treat one disease—had the potential to address other non-related co ...
Loading Comments...